Mathieu Bernier

Dr. Mathieu Bernier

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in JACC
Verified
Journal Article
Closed access
AFAfonso B. Freitas-Ferraz
Afonso B. Freitas-Ferraz
MBMathieu Bernier
Mathieu Bernier
RVRosaire Vaillancourt
Rosaire Vaillancourt
PUPaula A. Ugalde
Paula A. Ugalde
FNFrédéric Nicodème
Frédéric Nicodème
JRJosep Rodés-Cabau
Josep Rodés-Cabau

1 March 2020 in American Heart Journal
Verified
Journal Article
Closed access
AFAfonso B. Freitas-Ferraz
Afonso B. Freitas-Ferraz
JRJosep Rodés-Cabau
Josep Rodés-Cabau
LVLucía Junquera Vega
Lucía Junquera Vega
JBJonathan Beaudoin
Jonathan Beaudoin
KOKim O'COnnor
Kim O'COnnor
MBMathieu Bernier
Mathieu Bernier

18 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
ESErwan Salaun
Erwan Salaun
SDSamuel Drory
Samuel Drory
MCMarc‐André Coté
Marc‐André Coté
VTVeronic Tremblay
Veronic Tremblay
EBElisabeth Bédard
Elisabeth Bédard
STSébastien Thériault
Sébastien Thériault
Cardiac troponin is extensively used as a biomarker in modern medicine due to its diagnostic capability for myocardial injury, as well as its predictive and prognostic value for cardiac diseases. However, heterophile antibodies, antitroponin antibodies, and macrotroponin complexes can be observed both in seemingly healthy individuals and patients with cardiac diseases, potentially leading to false positive or disproportionate elevation of cTn (cardiac troponin) assay results and introducing discrepancies in clinical interpretations with impact on medical management. In this review article, we describe the possible mechanisms of cTn release and the sources of variations in the assessment of circulating cTn levels. We also explore the pathophysiological mechanisms underlying antitroponin antibody development and discuss the influence exerted by macrotroponin complexes on the results of immunoassays. Additionally, we explore approaches to detect these complexes by presenting various clinical scenarios encountered in routine clinical practice. Finally, unsolved questions about the development, prevalence, and clinical significance of cardiac autoantibodies are discussed.

1 July 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
QFQuentin Fischer
Quentin Fischer
DHDominique Himbert
Dominique Himbert
MBMathieu Bernier
Mathieu Bernier
MUMarina Urena
Marina Urena
AFAlfredo Nunes Ferreira-Neto
Alfredo Nunes Ferreira-Neto
JRJosep Rodés-Cabau
Josep Rodés-Cabau

25 November 2021 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
NDNicolas Dognin
Nicolas Dognin
ESErwan Salaun
Erwan Salaun
CCCatherine Champagne
Catherine Champagne
GDGuillaume Domain
Guillaume Domain
GOGilles O’hAra
Gilles O’hAra
JCJean champagne
Jean champagne

11 November 2022 in Structural Heart
Verified
Journal Article
Open access
ISIria Silva
Iria Silva
PTPierre Yves Turgeon
Pierre Yves Turgeon
JPJean-Michel Paradis
Jean-Michel Paradis
JBJonathan Beaudoin
Jonathan Beaudoin
KOKim O’cOnnor
Kim O’cOnnor
ESErwan Salaun
Erwan Salaun
The use of transcatheter edge-to-edge mitral valve repair (TEER) in symptomatic patients with severe mitral regurgitation (MR) has dramatically increased over the last few years. Current guidelines consider TEER as a reasonable option in symptomatic patients with primary or chronic secondary severe MR with high or prohibitive surgical risk and favorable anatomy. However, several anatomical and morphological mitral features have restricted the use of this mini-invasive technique in its early experience. The latest fourth generation (G4) of the MitraClip system has been recently introduced and includes the possibility of independent leaflet grasping and 4 different sizes. This technical update offers the possibility of selecting and combining multiple devices for complex mitral valve anatomies and challenging procedures, which helps expand the applications of TEER. The present review describes the potential advantages and the help of the MitraClip G4 devices to overcome various anatomic and morphologic issues in challenging cases with complex primary and secondary MR procedures.